<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03179761</url>
  </required_header>
  <id_info>
    <org_study_id>VICC CTT 1733</org_study_id>
    <secondary_id>NCI-2017-00466</secondary_id>
    <nct_id>NCT03179761</nct_id>
  </id_info>
  <brief_title>High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients</brief_title>
  <official_title>High vs. Standard Dose Flu Vaccine in Adult Stem Cell Transplant Recipients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt-Ingram Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt-Ingram Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized phase II studies the side effects of high-dose trivalent influenza vaccine or&#xD;
      standard-dose quadrivalent inactivated influenza and how well they work in treating adult&#xD;
      patients undergoing stem cell transplant. Season influenza can cause more severe infections&#xD;
      in patients who have had a stem cell transplant since their immune system doesn't work as&#xD;
      well. Influenza vaccine may provide better protection against flu in adults.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether high dose (HD)-trivalent influenza vaccine (TIV) compared with&#xD;
      standard dose (SD)-quadrivalent inactivated influenza vaccine (QIV) will increase the&#xD;
      probability of achieving a &gt;= 4-fold rise in hemagglutination inhibition assay (HAI) titer,&#xD;
      &gt;= 1:40 HAI titer, or a higher geometric mean titer (GMT) titer to influenza A antigens in&#xD;
      adult hematopoietic cell transplantation (HSCT) recipients.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To determine whether HD-TIV compared with SD-QIV will increase the probability of&#xD;
      achieving a &gt;= 4-fold rise in HAI titers, &gt;= 1:40 HAI titer, or higher GMT titers to&#xD;
      influenza B antigens in adult HSCT recipients.&#xD;
&#xD;
      II. To determine the frequency and severity of solicited local injection site adverse events&#xD;
      (e.g. pain/tenderness, redness, and swelling at injection site) with HD-TIV compared to&#xD;
      SD-QIV in adult HSCT recipients.&#xD;
&#xD;
      III. To determine the frequency and severity of solicited systemic adverse events (e.g.&#xD;
      fevers, headache, fatigue/malaise, nausea, body ache/myalgia, general activity level, and&#xD;
      vomiting) with HD-TIV compared to SD-QIV in adult HSCT recipients.&#xD;
&#xD;
      IV. To define the relationship between HAI titers, in vivo T and B cell phenotype, and in&#xD;
      vitro influenza-specific T and B cell response in adult HSCT recipients receiving either&#xD;
      HD-TIV or SD-QIV.&#xD;
&#xD;
      V. To correlate HAI responses to microneutralization responses. VI. To compare the persistent&#xD;
      HAI and microneutralization assay (MN) titers for all four antigen seven months after the&#xD;
      last vaccine dose to assess for persistence of antibody titers.&#xD;
&#xD;
      VII. To compare influenza detection by polymerase chain reaction (PCR) during influenza&#xD;
      season in adult HSCT recipients receiving either HD-TIV or standard dose QIV.&#xD;
&#xD;
      OUTLINE: Patients are randomized into 1 of 2 groups.&#xD;
&#xD;
      GROUP I: Patients receive HD-TIV intramuscularly once at baseline and once between 28-42&#xD;
      days.&#xD;
&#xD;
      GROUP II: Patients receive SD-QIV intramuscularly once at baseline and once between 28-42&#xD;
      days.&#xD;
&#xD;
      After completion of study treatment, patients are contacted at 1-3 and 8-10 days after each&#xD;
      vaccination visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 9, 2017</start_date>
  <completion_date type="Anticipated">March 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HD-TIV compared with SD-QIV (Influenza A) - immunogenicity</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Investigators will measure ≥4-fold rise in HAI titers, ≥1:40 HAI titer, or higher GMT titers to influenza A antigens</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HD-TIV compared with SD-QIV (Influenza B) - immunogenicity</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Investigators will measure ≥4-fold rise in HAI titers, ≥1:40 HAI titer, or higher GMT titers to influenza B antigens</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited local injection site adverse events</measure>
    <time_frame>Up to 10 days following each vaccination</time_frame>
    <description>Investigators will measure solicited adverse event (.e.g. pain/tenderness, redness, and swelling at injection site).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Solicited systemic adverse events</measure>
    <time_frame>Up to 10 days following each vaccination.</time_frame>
    <description>Investigators will measure solicited adverse event ((e.g. fevers, headache, fatigue/malaise, nausea, body ache/myalgia, general activity level, and vomiting).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of individuals in each group that test positive for influenza by PCR</measure>
    <time_frame>Up to 10 days following each vaccination</time_frame>
    <description>Testing of individuals nose swabs from influenza will be done, and compared to each group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of influenza-like illness in each group during the influenza season.</measure>
    <time_frame>Up to 10 days following each vaccination</time_frame>
    <description>Investigators will compare the number of illnesses between groups</description>
  </secondary_outcome>
  <other_outcome>
    <measure>B Cell (B Lymphocytes; B Cell; B-Cell; B-Lymphocyte; B Lymphocyte; Bursa-Dependent Lymphocytes; B-Cells; Bursa-Equivalent Lymphocyte; B-Lymphocytes)</measure>
    <time_frame>Up to 180 days</time_frame>
    <description>The total number of B cells will be measured prior to each vaccination and compared to each group.</description>
  </other_outcome>
  <other_outcome>
    <measure>T Cell (T Lymphocyte; T-Cell; Thymus-Dependent Lymphocytes; Thymus Derived Lymphocyte; T-Lymphocyte)</measure>
    <time_frame>Up to 180 days</time_frame>
    <description>The total number of T cells will be measured prior to each vaccination and compared to each group.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Hematopoietic Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Group I (HD-TIV)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive HD-TIV intramuscularly once at baseline and once between 28-42 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2(SD-QIV)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive SD-QIV intramuscularly once at baseline and once between 28-42 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Quadrivalent Inactivated Influenza Vaccine</intervention_name>
    <description>Given intramuscularly</description>
    <arm_group_label>Group 2(SD-QIV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Group 2(SD-QIV)</arm_group_label>
    <arm_group_label>Group I (HD-TIV)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trivalent Influenza Vaccine</intervention_name>
    <description>Given intramuscularly</description>
    <arm_group_label>Group I (HD-TIV)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Allogeneic HSCT recipients who are 3-23 months post-transplant&#xD;
&#xD;
          -  Available for duration of study&#xD;
&#xD;
          -  If patients are on immunosuppressive therapy for treatment of graft versus host&#xD;
             disease (GVHD), then only those on stable doses for at least 4 weeks (or on tapering&#xD;
             doses) will be eligible&#xD;
&#xD;
          -  Can be reached by telephone or email&#xD;
&#xD;
          -  Subjects must have a platelet count of &gt;= 30,000 to receive the immunizations;&#xD;
             patients requiring platelet transfusions are eligible to enroll and must have a&#xD;
             platelet count &gt;= 30,000 within 72 hours prior to their immunization; for subjects &lt;&#xD;
             12 months post-transplant, if a platelet count of &gt;= 75,000 is documented without&#xD;
             transfusion support within 14 days of the immunization, then an additional platelet&#xD;
             count does not need to be repeated prior to immunization; for subjects 12-23 months&#xD;
             post-transplant, if a platelet count of &gt;= 75,000 is documented without transfusion&#xD;
             support within 90 days of the immunization, then an additional platelet count does not&#xD;
             need to be repeated prior to immunization&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of hypersensitivity to previous influenza vaccination or severe or moderate&#xD;
             hypersensitivity to eggs/egg protein&#xD;
&#xD;
          -  History of Guillain-Barre syndrome&#xD;
&#xD;
          -  Evidence of hematologic malignancy or disease relapse post-transplant (stable mixed&#xD;
             chimerisms are permitted)&#xD;
&#xD;
          -  History of receiving 2017-2018 influenza vaccine&#xD;
&#xD;
          -  Pregnant female&#xD;
&#xD;
          -  History of proven influenza disease after September 1, 2017&#xD;
&#xD;
          -  Non-allogeneic (e.g. autologous) or syngeneic hematopoietic stem cell transplant (SCT)&#xD;
             recipients&#xD;
&#xD;
          -  History of known active infection with human immunodeficiency virus (HIV), hepatitis&#xD;
             B, or hepatitis C&#xD;
&#xD;
          -  History of known latex hypersensitivity&#xD;
&#xD;
          -  Subjects who have received stem cell boost or delayed donor lymphocyte infusion within&#xD;
             90 days of enrollment, including day of enrollment&#xD;
&#xD;
          -  Receipt of intravenous immunoglobulin therapy (IVIG) &lt; 27 days prior to vaccination&#xD;
&#xD;
          -  CD34 selection or total cell depletion outside haploidentical transplants&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Alabama</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 1, 2017</study_first_submitted>
  <study_first_submitted_qc>June 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2017</study_first_posted>
  <last_update_submitted>June 15, 2021</last_update_submitted>
  <last_update_submitted_qc>June 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt-Ingram Cancer Center</investigator_affiliation>
    <investigator_full_name>Natasha Halasa, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/61/NCT03179761/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

